share_log

Cardiovascular Systems (NASDAQ:CSII) Sees Large Volume Increase

Cardiovascular Systems (NASDAQ:CSII) Sees Large Volume Increase

心血管系统(纳斯达克:CSII)销量大幅增长
Defense World ·  2022/09/15 06:12

Cardiovascular Systems, Inc. (NASDAQ:CSII – Get Rating) saw strong trading volume on Tuesday . 22,955 shares traded hands during mid-day trading, a decline of 90% from the previous session's volume of 223,037 shares.The stock last traded at $13.87 and had previously closed at $14.16.

心血管系统公司(纳斯达克代码:CSII-GET评级)周二成交量强劲。午盘成交量为22,955股,较前一交易日的223,037股下跌90%。该股最新报13.87美元,此前收盘价为14.16美元。

Cardiovascular Systems Stock Up 3.3 %

心血管系统股票上涨3.3%

The company has a debt-to-equity ratio of 0.08, a current ratio of 6.05 and a quick ratio of 5.19. The firm has a fifty day moving average of $15.14 and a 200 day moving average of $17.10.

该公司的负债权益比为0.08,流动比率为6.05,速动比率为5.19。该公司的50日移动均线切入位在15.14美元,200日移动均线切入位在17.10美元。

Get
到达
Cardiovascular Systems
心血管系统
alerts:
警报:

Institutional Investors Weigh In On Cardiovascular Systems

机构投资者参与心血管系统

Several hedge funds and other institutional investors have recently made changes to their positions in CSII. Assenagon Asset Management S.A. increased its holdings in shares of Cardiovascular Systems by 116.3% in the second quarter. Assenagon Asset Management S.A. now owns 859,065 shares of the medical device company's stock valued at $12,336,000 after purchasing an additional 461,931 shares during the last quarter. Cubist Systematic Strategies LLC increased its holdings in shares of Cardiovascular Systems by 579.7% in the second quarter. Cubist Systematic Strategies LLC now owns 318,511 shares of the medical device company's stock valued at $4,574,000 after purchasing an additional 271,649 shares during the last quarter. Grandeur Peak Global Advisors LLC increased its holdings in shares of Cardiovascular Systems by 36.2% in the fourth quarter. Grandeur Peak Global Advisors LLC now owns 564,582 shares of the medical device company's stock valued at $10,603,000 after purchasing an additional 150,103 shares during the last quarter. BNP Paribas Arbitrage SA increased its holdings in shares of Cardiovascular Systems by 344.6% in the fourth quarter. BNP Paribas Arbitrage SA now owns 171,228 shares of the medical device company's stock valued at $3,216,000 after purchasing an additional 132,716 shares during the last quarter. Finally, Walleye Capital LLC increased its holdings in shares of Cardiovascular Systems by 185.5% in the fourth quarter. Walleye Capital LLC now owns 200,015 shares of the medical device company's stock valued at $3,756,000 after purchasing an additional 129,967 shares during the last quarter. Institutional investors and hedge funds own 91.72% of the company's stock.

几家对冲基金和其他机构投资者最近调整了他们在CSII的头寸。Assenagon Asset Management S.A.在第二季度增持了116.3%的心血管系统股票。Assenagon Asset Management S.A.在上个季度额外购买了461,931股后,现在拥有这家医疗设备公司859,065股股票,价值12,336,000美元。立体主义系统战略有限责任公司在第二季度增持了心血管系统公司的股票579.7%。Cubist Systems Strategy LLC在上个季度额外购买了271,649股后,现在拥有这家医疗设备公司318,511股股票,价值4,574,000美元。宏伟顶峰全球顾问有限责任公司在第四季度增持了心血管系统公司的股票36.2%。宏伟的Peak Global Advisors LLC现在持有这家医疗设备公司564,582股股票,价值10,603,000美元,上个季度又购买了150,103股。法国巴黎银行套利公司在第四季度增持了344.6%的心血管系统股票。法国巴黎银行套利公司现在拥有171,228股这家医疗设备公司的股票,价值321.6万美元,在上个季度又购买了132,716股。最后,Walleye Capital LLC在第四季度增持了185.5%的心血管系统公司股票。Walleye Capital LLC现在拥有这家医疗设备公司200,015股股票,价值3756,000美元,上个季度又购买了129,967股。机构投资者和对冲基金持有该公司91.72%的股票。

Cardiovascular Systems Company Profile

心血管系统公司简介

(Get Rating)
(获取评级)

Cardiovascular Systems, Inc, a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products.

心血管系统公司是一家医疗技术公司,在美国和国际上开发和销售治疗外周和冠状动脉疾病的解决方案。该公司提供外周动脉疾病产品,包括基于导管的平台,用于治疗膝盖以上和膝盖以下的各种斑块类型,包括钙化斑块,以及解决与手术、导管和药物治疗替代方案相关的各种限制;以及外周支持产品。

Read More

阅读更多内容

  • Get a free copy of the StockNews.com research report on Cardiovascular Systems (CSII)
  • Murphy USA Outperforming Other Mid-caps, But Is It A Buy Now?
  • Has 3M Reached the Point of Being so Bad It's Good?
  • Is This Medical Gear Maker Ready To Continue Its Rally?
  • The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
  • Has Take-Two Interactive Devolved into a One-Trick Pony?
  • 免费获取StockNews.com心血管系统研究报告(CSII)
  • 墨菲美国的表现好于其他中型股,但它现在值得吗?
  • 3M已经到了坏到好的地步了吗?
  • 这家医疗设备制造商准备好继续反弹了吗?
  • 第三季度财报公布前最值得关注的五(5)只股票
  • Take-Two Interactive是否已经退化为一招小马?

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.

接受《每日心血管系统》新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对心血管系统和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发